TerminatedPhase 1

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Stopped: The research was terminated voluntarily due to changes in the company's business strategy regarding the development of BGB-24714, rather than any safety issues.

United States157 participantsStarted 2022-07-06

Plain-language summary

This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
✕. Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
✕. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before the first dose of study drug(s).
✕. Clinically significant infection requiring systemic therapy ≤ 14 days before the first dose of study drug(s).
✕. Prior exposure to agents with second mitochondria-derived activator of caspases (SMAC) mimetics, or other Inhibitors of apoptosis proteins (IAPs) antagonists.

What they're measuring

Dose Escalation: Number of participants with adverse events (AEs)

Timeframe: approximately 6 months

Dose Escalation: Maximum tolerated dose (MTD) of BGB-24714 as monotherapy, in combination with chemotherapy, and in combination with concurrent chemoradiotherapy (cCRT)

Timeframe: approximately 6 months

Dose Escalation: Recommended Doses for Expansion (RDFE) of BGB-24714 as monotherapy, in combination with chemotherapy, and in combination with concurrent chemoradiotherapy (cCRT)

Timeframe: approximately 6 months

Dose Expansion: Objective response rate (ORR)

Timeframe: approximately 2 Years

Trial details

NCT IDNCT05381909

SponsorBeiGene

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-07-25

View on ClinicalTrials.gov More Solid Tumor, Adult trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
✕. Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
✕. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before the first dose of study drug(s).
✕. Clinically significant infection requiring systemic therapy ≤ 14 days before the first dose of study drug(s).
✕. Prior exposure to agents with second mitochondria-derived activator of caspases (SMAC) mimetics, or other Inhibitors of apoptosis proteins (IAPs) antagonists.

What they're measuring

Dose Escalation: Number of participants with adverse events (AEs)

Timeframe: approximately 6 months

Dose Escalation: Maximum tolerated dose (MTD) of BGB-24714 as monotherapy, in combination with chemotherapy, and in combination with concurrent chemoradiotherapy (cCRT)

Timeframe: approximately 6 months

Dose Escalation: Recommended Doses for Expansion (RDFE) of BGB-24714 as monotherapy, in combination with chemotherapy, and in combination with concurrent chemoradiotherapy (cCRT)

Timeframe: approximately 6 months

Dose Expansion: Objective response rate (ORR)

Timeframe: approximately 2 Years